Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 445 to 451 of 451 entries
Sorted by: Best Match Show Resources per page
Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.

European journal of heart failure

Curtain JP, Jackson A, Shen L, Jhund PS, Docherty KF, Petrie MC, Castagno D, Desai AS, Rohde LE, Lefkowitz MP, Rouleau JL, Zile MR, Solomon SD, Swedberg K, Packer M, McMurray JJV.
PMID: 34969175
Eur J Heart Fail. 2021 Dec 30; doi: 10.1002/ejhf.2419. Epub 2021 Dec 30.

BACKGROUND: Sudden death is a leading cause of mortality in HFrEF. In PARADIGM-HF, sacubitril/valsartan reduced the incidence of sudden death. The purpose of this post hoc study was to analyze the effect of sacubitril/valsartan, compared to enalapril, on the...

Cite
Curtain JP, Jackson A, Shen L, et al. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2021;doi: 10.1002/ejhf.2419.
Curtain, J. P., Jackson, A., Shen, L., Jhund, P. S., Docherty, K. F., Petrie, M. C., Castagno, D., Desai, A. S., Rohde, L. E., Lefkowitz, M. P., Rouleau, J. L., Zile, M. R., Solomon, S. D., Swedberg, K., Packer, M., & McMurray, J. J. V. (2021). Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European journal of heart failure, . https://doi.org/10.1002/ejhf.2419
Curtain, James P, et al. "Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF." European journal of heart failure vol. (2021). doi: https://doi.org/10.1002/ejhf.2419
Curtain JP, Jackson A, Shen L, Jhund PS, Docherty KF, Petrie MC, Castagno D, Desai AS, Rohde LE, Lefkowitz MP, Rouleau JL, Zile MR, Solomon SD, Swedberg K, Packer M, McMurray JJV. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. Eur J Heart Fail. 2021 Dec 30; doi: 10.1002/ejhf.2419. Epub 2021 Dec 30. PMID: 34969175.
Copy Download .nbib Format: NLM
Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats.

Biochimica et biophysica acta. Molecular basis of disease

Panthiya L, Tocharus J, Onsa-Ard A, Chaichompoo W, Suksamrarn A, Tocharus C.
PMID: 34883248
Biochim Biophys Acta Mol Basis Dis. 2021 Dec 07;1868(3):166317. doi: 10.1016/j.bbadis.2021.166317. Epub 2021 Dec 07.

Hexahydrocurcumin (HHC), a major metabolite of curcumin, possesses several biological activities such as antioxidant, anti-inflammation, and cardioprotective properties. This study aimed to investigate the effect of HHC on high blood pressure, vascular dysfunction, and remodeling induced by N-nitro L-arginine...

Cite
Panthiya L, Tocharus J, Onsa-Ard A, et al. Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats. Biochim Biophys Acta Mol Basis Dis. 2021;1868(3):166317doi: 10.1016/j.bbadis.2021.166317.
Panthiya, L., Tocharus, J., Onsa-Ard, A., Chaichompoo, W., Suksamrarn, A., & Tocharus, C. (2021). Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats. Biochimica et biophysica acta. Molecular basis of disease, 1868(3), 166317. https://doi.org/10.1016/j.bbadis.2021.166317
Panthiya, Luckika, et al. "Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats." Biochimica et biophysica acta. Molecular basis of disease vol. 1868,3 (2021): 166317. doi: https://doi.org/10.1016/j.bbadis.2021.166317
Panthiya L, Tocharus J, Onsa-Ard A, Chaichompoo W, Suksamrarn A, Tocharus C. Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats. Biochim Biophys Acta Mol Basis Dis. 2021 Dec 07;1868(3):166317. doi: 10.1016/j.bbadis.2021.166317. Epub 2021 Dec 07. PMID: 34883248.
Copy Download .nbib Format: NLM
Intravital imaging reveals glomerular capillary distension and endothelial and immune cell activation early in Alport syndrome.

JCI insight

Gyarmati G, Shroff UN, Izuhara A, Hou X, Da Sacco S, Sedrakyan S, Lemley KV, Amann K, Perin L, Peti-Peterdi J.
PMID: 34793332
JCI Insight. 2021 Nov 18; doi: 10.1172/jci.insight.152676. Epub 2021 Nov 18.

Alport syndrome (AS) is a genetic disorder caused by mutations in type IV collagen that leads to defective glomerular basement membrane, glomerular filtration barrier (GFB) damage, and progressive chronic kidney disease. While the genetic basis of AS is well...

Cite
Gyarmati G, Shroff UN, Izuhara A, et al. Intravital imaging reveals glomerular capillary distension and endothelial and immune cell activation early in Alport syndrome. JCI Insight. 2021;doi: 10.1172/jci.insight.152676.
Gyarmati, G., Shroff, U. N., Izuhara, A., Hou, X., Da Sacco, S., Sedrakyan, S., Lemley, K. V., Amann, K., Perin, L., & Peti-Peterdi, J. (2021). Intravital imaging reveals glomerular capillary distension and endothelial and immune cell activation early in Alport syndrome. JCI insight, . https://doi.org/10.1172/jci.insight.152676
Gyarmati, Georgina, et al. "Intravital imaging reveals glomerular capillary distension and endothelial and immune cell activation early in Alport syndrome." JCI insight vol. (2021). doi: https://doi.org/10.1172/jci.insight.152676
Gyarmati G, Shroff UN, Izuhara A, Hou X, Da Sacco S, Sedrakyan S, Lemley KV, Amann K, Perin L, Peti-Peterdi J. Intravital imaging reveals glomerular capillary distension and endothelial and immune cell activation early in Alport syndrome. JCI Insight. 2021 Nov 18; doi: 10.1172/jci.insight.152676. Epub 2021 Nov 18. PMID: 34793332.
Copy Download .nbib Format: NLM
Finding a cell-permeable compound to inhibit inflammatory cytokines: Uptake, biotransformation, and anti-cytokine activity of javamide-I/-II esters.

Life sciences

Park JB.
PMID: 34982964
Life Sci. 2022 Jan 01;291:120280. doi: 10.1016/j.lfs.2021.120280. Epub 2022 Jan 01.

AIM: Currently, there is limited information available about cell-permeability and anti-cytokine activity of javamide-I/-II esters in monocyte/macrophage-like cells. Therefore, the aim of this study was to investigate their cell-permeability and anti-cytokine activity in the cells.MATERIALS AND METHODS: The uptake...

Cite
Park JB. Finding a cell-permeable compound to inhibit inflammatory cytokines: Uptake, biotransformation, and anti-cytokine activity of javamide-I/-II esters. Life Sci. 2022;291:120280doi: 10.1016/j.lfs.2021.120280.
Park, J. B. (2022). Finding a cell-permeable compound to inhibit inflammatory cytokines: Uptake, biotransformation, and anti-cytokine activity of javamide-I/-II esters. Life sciences, 291120280. https://doi.org/10.1016/j.lfs.2021.120280
Park, Jae B. "Finding a cell-permeable compound to inhibit inflammatory cytokines: Uptake, biotransformation, and anti-cytokine activity of javamide-I/-II esters." Life sciences vol. 291 (2022): 120280. doi: https://doi.org/10.1016/j.lfs.2021.120280
Park JB. Finding a cell-permeable compound to inhibit inflammatory cytokines: Uptake, biotransformation, and anti-cytokine activity of javamide-I/-II esters. Life Sci. 2022 Jan 01;291:120280. doi: 10.1016/j.lfs.2021.120280. Epub 2022 Jan 01. PMID: 34982964.
Copy Download .nbib Format: NLM
A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia.

Urology journal

Farshi A, DalirAkbari N, Zomorrodi A, Khalili M, Mahmoudinezhad M.
PMID: 33840085
Urol J. 2021 Apr 11;18(3):337-342. doi: 10.22037/uj.v18i.5678.

PURPOSE: The present study aims to assess and compare the effects of carvedilol and terazosin plus enalapril on lower urinary tract symptoms (LUTS), the urine flow, and blood pressure (BP) in patients with moderate hypertension (HTN) and benign prostatic...

Cite
Farshi A, DalirAkbari N, Zomorrodi A, et al. A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. Urol J. 2021;18(3):337-342doi: 10.22037/uj.v18i.5678.
Farshi, A., DalirAkbari, N., Zomorrodi, A., Khalili, M., & Mahmoudinezhad, M. (2021). A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. Urology journal, 18(3), 337-342. https://doi.org/10.22037/uj.v18i.5678
Farshi, Alireza, et al. "A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia." Urology journal vol. 18,3 (2021): 337-342. doi: https://doi.org/10.22037/uj.v18i.5678
Farshi A, DalirAkbari N, Zomorrodi A, Khalili M, Mahmoudinezhad M. A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. Urol J. 2021 Apr 11;18(3):337-342. doi: 10.22037/uj.v18i.5678. PMID: 33840085.
Copy Download .nbib Format: NLM
Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats.

Biochimica et biophysica acta. Molecular basis of disease

Panthiya L, Tocharus J, Onsa-Ard A, Chaichompoo W, Suksamrarn A, Tocharus C.
PMID: 34883248
Biochim Biophys Acta Mol Basis Dis. 2021 Dec 07;1868(3):166317. doi: 10.1016/j.bbadis.2021.166317. Epub 2021 Dec 07.

Hexahydrocurcumin (HHC), a major metabolite of curcumin, possesses several biological activities such as antioxidant, anti-inflammation, and cardioprotective properties. This study aimed to investigate the effect of HHC on high blood pressure, vascular dysfunction, and remodeling induced by N-nitro L-arginine...

Cite
Panthiya L, Tocharus J, Onsa-Ard A, et al. Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats. Biochim Biophys Acta Mol Basis Dis. 2021;1868(3):166317doi: 10.1016/j.bbadis.2021.166317.
Panthiya, L., Tocharus, J., Onsa-Ard, A., Chaichompoo, W., Suksamrarn, A., & Tocharus, C. (2021). Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats. Biochimica et biophysica acta. Molecular basis of disease, 1868(3), 166317. https://doi.org/10.1016/j.bbadis.2021.166317
Panthiya, Luckika, et al. "Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats." Biochimica et biophysica acta. Molecular basis of disease vol. 1868,3 (2021): 166317. doi: https://doi.org/10.1016/j.bbadis.2021.166317
Panthiya L, Tocharus J, Onsa-Ard A, Chaichompoo W, Suksamrarn A, Tocharus C. Hexahydrocurcumin ameliorates hypertensive and vascular remodeling in L-NAME-induced rats. Biochim Biophys Acta Mol Basis Dis. 2021 Dec 07;1868(3):166317. doi: 10.1016/j.bbadis.2021.166317. Epub 2021 Dec 07. PMID: 34883248.
Copy Download .nbib Format: NLM
Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis.

Clinical drug investigation

Teo YN, Teo YH, Syn NL, Yoong CSY, Cheong AJY, Wee CF, Lim YC, Lee CH, Yeo TC, Chai P, Wong RCC, Lin W, Sia CH.
PMID: 34797518
Clin Drug Investig. 2022 Jan;42(1):1-16. doi: 10.1007/s40261-021-01098-3. Epub 2021 Nov 19.

BACKGROUND AND OBJECTIVE: In recent trials, sodium-glucose cotransporter 2 (SGLT2) inhibitors proved effective as treatment for heart failure. However, the relative efficacy of sacubitril/valsartan against SGLT2 inhibitor in patients with heart failure remains unknown. Hence, we performed a network...

Cite
Teo YN, Teo YH, Syn NL, et al. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clin Drug Investig. 2021;42(1):1-16doi: 10.1007/s40261-021-01098-3.
Teo, Y. N., Teo, Y. H., Syn, N. L., Yoong, C. S. Y., Cheong, A. J. Y., Wee, C. F., Lim, Y. C., Lee, C. H., Yeo, T. C., Chai, P., Wong, R. C. C., Lin, W., & Sia, C. H. (2022). Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clinical drug investigation, 42(1), 1-16. https://doi.org/10.1007/s40261-021-01098-3
Teo, Yao Neng, et al. "Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis." Clinical drug investigation vol. 42,1 (2022): 1-16. doi: https://doi.org/10.1007/s40261-021-01098-3
Teo YN, Teo YH, Syn NL, Yoong CSY, Cheong AJY, Wee CF, Lim YC, Lee CH, Yeo TC, Chai P, Wong RCC, Lin W, Sia CH. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis. Clin Drug Investig. 2022 Jan;42(1):1-16. doi: 10.1007/s40261-021-01098-3. Epub 2021 Nov 19. PMID: 34797518.
Copy Download .nbib Format: NLM
Showing 445 to 451 of 451 entries